Literature DB >> 11216381

Prenatal diagnosis and treatment of steroid 21-hydroxylase deficiency (congenital adrenal hyperplasia).

R Mathur1, M Kabra.   

Abstract

Steroid 21-hydroxylase deficiency congenital adrenal hyperplasia is the most common cause of genital ambiguity in females at birth. Inhibited formation of cortisol causes increase in the release of ACTH in turn leading to overproduction of adrenal androgens. This predisposes the affected female fetus to prenatal development of genital ambiguity. A large number of patients also have aldosterone insufficiency which manifests after birth in form of inability to conserve sodium and to excrete potassium which can lead to adrenal shock and neonatal death, if left untreated. Prenatal diagnosis is possible using several methods like steroid assay of amniotic fluid and, HLA typing. Recently with advancement more accurate direct molecular genetic techniques have been utilized on chorionic villus samples in first trimester of pregnancy. Prenatal treatment is also possible and pregnancies can be managed by administering dexamethasone to the mother as soon as pregnancy is diagnosed. This suppresses fetal androgen production in genetic females preventing virilization and leading to normal development. Prenatal diagnosis and treatment are highly desirable in families with a positive family history towards birth of a child without features of the disease.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11216381     DOI: 10.1007/bf02726225

Source DB:  PubMed          Journal:  Indian J Pediatr        ISSN: 0019-5456            Impact factor:   1.967


  26 in total

Review 1.  Molecular biology of steroid hormone synthesis.

Authors:  W L Miller
Journal:  Endocr Rev       Date:  1988-08       Impact factor: 19.871

2.  Utility of XY-amelogenin gene primers for detection of sex chromosomes.

Authors:  M R Chowdhury; R Mathur; I C Verma
Journal:  Indian J Med Res       Date:  1998-04       Impact factor: 2.375

Review 3.  Basic and clinical aspects of congenital adrenal hyperplasia.

Authors:  M I New
Journal:  J Steroid Biochem       Date:  1987       Impact factor: 4.292

4.  Prenatal diagnosis of congenital adrenal hyperplasia due to 21-hydroxylase deficiency by allele-specific hybridization and Southern blot.

Authors:  P W Speiser; P C White; J Dupont; D Zhu; A B Mercado; M I New
Journal:  Hum Genet       Date:  1994-04       Impact factor: 4.132

5.  Diagnosis of the adrenogenital syndrome before birth.

Authors:  T N Jeffcoate; J R Fliegner; S H Russell; J C Davis; A P Wade
Journal:  Lancet       Date:  1965-09-18       Impact factor: 79.321

6.  Profiling steroid hormones in amniotic fluid of midpregnancy by routine stable isotope dilution/gas chromatography-mass spectrometry: reference values and concentrations in fetuses at risk for 21-hydroxylase deficiency.

Authors:  S A Wudy; H G Dörr; C Solleder; M Djalali; J Homoki
Journal:  J Clin Endocrinol Metab       Date:  1999-08       Impact factor: 5.958

7.  Prenatal diagnosis/treatment in families at risk for infants with steroid 21-hydroxylase deficiency (congenital adrenal hyperplasia).

Authors:  L P Karaviti; A B Mercado; M B Mercado; P W Speiser; M Buegeleisen; C Crawford; L Antonian; P C White; M I New
Journal:  J Steroid Biochem Mol Biol       Date:  1992-03       Impact factor: 4.292

8.  Prenatal treatment and diagnosis of congenital adrenal hyperplasia owing to steroid 21-hydroxylase deficiency.

Authors:  A B Mercado; R C Wilson; K C Cheng; J Q Wei; M I New
Journal:  J Clin Endocrinol Metab       Date:  1995-07       Impact factor: 5.958

9.  Prenatal dexamethasone treatment in pregnancies at risk for congenital adrenal hyperplasia due to 21-hydroxylase deficiency: effect on midgestational amniotic fluid steroid levels.

Authors:  H G Dörr; W G Sippell
Journal:  J Clin Endocrinol Metab       Date:  1993-01       Impact factor: 5.958

10.  Congenital adrenal hyperplasia: a potential diagnosis for the neonate in shock.

Authors:  J Pearce
Journal:  Aust Crit Care       Date:  1995-03       Impact factor: 2.737

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.